GlobeNewswire by notified

Ceylon Graphite Announces Licence for Vein Graphite and Graphene Technologies

Share

VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”).

This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how. Use of Ceylon’s high-grade feedstock material- vein graphite - leads to minimal to nil industrial waste during the production of graphene. The combination of unique raw materials and eco-friendly, low-cost production process, places Ceylon in a position to offer high quality graphene products at an attractive price.

The graphene market has been growing at a significant rate, and a number of potential customers have indicated their interest in joint development and/or collaboration in graphene product applications. Ceylon has commenced its graphene product validation in a myriad of industrial applications. In particular, use of resultant graphene in Silicon additive utilization technology for Li-ion batteries is shown to be promising. This opens up a whole new technology area for Ceylon Graphite’s value added product range.

Ceylon CEO, Don Baxter stated, ”I am excited for Ceylon to have this technology. In the past talk of graphene has always been on a micro scale and issues around production of large quantities was always a hurdle to overcome. Ceylon has acquired an industrial scale process that will allow us to utilize graphene additives in commercial applications developed by Drs Siva and Mallika Bohm. The onset of the EV revolution has provided an opportunity for Ceylon to contribute in a meaningful way, through enhancements to the graphite anode in a lithium ion battery.”           

Qualified Person

Donald K.D. Baxter, P. Eng. is a Qualified Person under National Instrument 43-101 and has reviewed and approved the technical information provided in this news release.

About Ceylon Graphite Corp.
Ceylon Graphite is a public company listed on the TSX Venture Exchange, that is in the business of mining for graphite, and developing and commercializing innovative graphene and graphite applications and products. Graphite mined in Sri Lanka is known to be some of the purest in the world and has been confirmed to be suitable to be easily upgradable for a range of applications including the high-growth electric vehicle and battery storage markets as well as construction, healthcare and paints and coatings sectors. The Government of Sri Lanka has granted the Company’s wholly owned subsidiary Sarton Development (Pvt) Ltd. an IML Category A license for its K1 mine and exploration rights in a land package of over 120km². These exploration grids (each one square kilometer in area) cover areas of historic graphite production from the early twentieth century and represent a majority of the known graphite occurrences in Sri Lanka.

Further information regarding the Company is available at www.ceylongraphite.com

Don Baxter, Chief Executive Officer
info@ceylongraphite.com
Corporate Communications
1 604-765-8657

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD LOOKING STATEMENTS:

This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management's current expectations and assumptions. The forward-looking information includes statements about Ceylon Graphite’s grids, Ceylon Graphite’s plans to undertake additional drilling and to develop a mine plan, and to commence establishing mining operations. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to Ceylon Graphite, including the assumption that, there will be no material adverse change in metal prices, all necessary consents, licenses, permits and approvals will be obtained, including various Local Government Licenses and the market. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things, an inability to reach a final acquisition agreement, inaccurate results from the drilling exercises, a failure to obtain or delays in obtaining the required regulatory licenses, permits, approvals and consents, an inability to access financing as needed, a general economic downturn, a volatile stock price, labour strikes, political unrest, changes in the mining regulatory regime governing Ceylon Graphite, a failure to comply with environmental regulations and a weakening of market and industry reliance on high quality graphite. Ceylon Graphite cautions the reader that the above list of risk factors is not exhaustive.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye